AstraZeneca to buy U.S. cancer firm for up to $500 million

Reuters via Yahoo

AstraZeneca took a further step to bolster its pipeline of new cancer drugs on Monday by agreeing to acquire privately held U.S. biotech company Amplimmune for up to $500 million.

Letter
to the
Editor

Send us a letter

Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

Recommended for You
U.S. Food and Drug Administration (FDA)
Upcoming FDA draft on pulse oximetry's racial bias draws questions
Most Popular
1
Bullets in UnitedHealthcare CEO death inscribed with ‘depose,’ ‘delay’
2
UnitedHealthcare CEO Brian Thompson's killing shocks industry
3
Sutter Health Plus taps ex-Cigna exec as CEO
4
UnitedHealthcare CEO killing puts new focus on exec safety policy
5
Soda Health gets $50M to manage MA supplemental benefits